4D Molecular Therapeutics' 4D-150 Receives RMAT Designation For Diabetic Macular Edema
1/5 16:15
(RTTNews) - 4D Molecular Therapeutics (FDMT), Thursday announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to its gene therapy candidate 4D-150 for diabetic macular edema. This marks the second retinal vascular disease after wet age-related macul...